Drug intelligence / Profile preview

ABG-023

Development stage: Preclinical
Lead developer: AmideBio
Modality: Peptides, Small Molecules
Administration: Subcutaneous, Intravenous, Intramuscular

Overview

ABG-023 is a solution-stable, soluble glucagon analog developed by AmideBio for the treatment of congenital hyperinsulinism (CHI). It is designed to overcome the limitations of native glucagon, which is effective in treating CHI but impractical for long-term administration due to its instability in solution. ABG-023 maintains efficacy while offering improved stability, making it suitable for continuous delivery systems such as pumps. The drug acts as an **agonist of the glucagon receptor**. The drug has received Orphan Drug designation from the FDA and may also have potential use in emergency hypoglycemia management.

Other names: ABG-023ABG023ABG 023

Targets

GCGR (Glucagon receptor)

Beyond the preview

Go deeper on ABG-023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABG-023.

Explore the full profile